"Genistein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An isoflavonoid derived from soy products. It inhibits PROTEIN-TYROSINE KINASE and topoisomerase-II (DNA TOPOISOMERASES, TYPE II); activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 PHASE arrest in human and murine cell lines and inhibits PROTEIN-TYROSINE KINASE.
| Descriptor ID |
D019833
|
| MeSH Number(s) |
D03.383.663.283.266.450.400.375 D03.633.100.150.266.450.400.375
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Genistein".
Below are MeSH descriptors whose meaning is more specific than "Genistein".
This graph shows the total number of publications written about "Genistein" by people in this website by year, and whether "Genistein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 2 | 0 | 2 |
| 2004 | 2 | 2 | 4 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 5 | 1 | 6 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genistein" by people in Profiles.
-
Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial. JAMA. 2015 May 26; 313(20):2033-43.
-
Soy promotes juvenile granulosa cell tumor development in mice and in the human granulosa cell tumor-derived COV434 cell line. Biol Reprod. 2014 Oct; 91(4):100.
-
Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. Anticancer Agents Med Chem. 2012 Dec; 12(10):1264-80.
-
Effects of estrogen and estrus cycle on pharmacokinetics, absorption, and disposition of genistein in female Sprague-Dawley rats. J Agric Food Chem. 2012 Aug 15; 60(32):7949-56.
-
Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein. Drug Metab Dispos. 2012 Oct; 40(10):1883-93.
-
SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells can be explained by the relevant molecular docking studies. Mol Pharm. 2012 Apr 02; 9(4):862-73.
-
UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP. Drug Metab Dispos. 2012 Feb; 40(2):336-45.
-
A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1033-44.
-
Genistein regulated serotonergic activity in the hippocampus of ovariectomized rats under forced swimming stress. Biosci Biotechnol Biochem. 2010; 74(10):2005-10.
-
Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine. AAPS J. 2010 Dec; 12(4):525-36.